Navigation Links
ASEAN News: Epeius Biotechnologies Gains Commercial Approval for Rexin-G(R), a Tumor-Targeted Gene-Based Medicine for Metastatic Cancer
Date:12/18/2007

bedside."

Now that Rexin-G is commercially available to Philippine physicians and their patients, and to a host of medical tourists from the United States, Europe, and Japan, the next step is to expand its availability to these countries and to ASEAN countries that share cooperative affiliations with the Philippines. Epeius Biotechnologies has intensified its efforts to gain product registration in the United States-following several years of safety studies in the USA, Epeius has formally opened three advanced Phase I/II trials in San Marino and Santa Monica, California, for chemo-resistant pancreatic cancer, breast cancer, and sarcoma. Based again on unprecedented single-agent efficacy and over-all safety, the US FDA recently approved a Phase II Registration Protocol for osteosarcoma which includes participation of children and adolescents. For additional information about ongoing clinical trials in the United States, contact our Medical Director, Dr. Erlinda M. Gordon at egordon@epeiusbiotech.com.

About Epeius Biotechnologies

Epeius Biotechnologies Corporation is a privately held biopharmaceutical company dedicated to the advancement of genetic medicine with the development and commercialization of its lead products and proprietary targeted delivery systems. Credited with innovations ranging from gene discovery, to designer therapeutic genes, to pathotropic (disease-seeking) targeting, to ultra high-performance vector engineering, to advanced biopharmaceutical manufacturing and bioprocess development, Epeius Biotechnologies is well positioned to 'launch' its enabling platform technologies for the benefit of cancer patients worldwide. Meanwhile, rapid advances in clinical drug development provide Epeius with a unique opportunity for early revenues from the sale of its lead product to the Philippines and reciprocating ASEAN countries -- thus demonstrating the high growth potential of a small biotec
'/>"/>

SOURCE Epeius Biotechnologies Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related medicine technology :

1. Vical Begins Phase 1 Trial of DNA Vaccine Against H5N1 Pandemic Influenza
2. Oritavancin Demonstrates Superior In Vitro Activity to Vancomycin and Metronidazole Against C. Difficile Bacteria
3. Oritavancin Demonstrates Potent and Rapid In Vitro Activity Against MRSA, VRE and Other Strains of Resistant Bacteria
4. Molnlycke Drives Home the Fight Against Staph and Other MRSA Infections
5. Mayo Clinic Study Finds FDA Warning Against Anti-Nausea Drug Droperidol Unnecessary
6. Targeted Nanoparticles Offer Promise in the Battle Against Cancer
7. Interim Safety Data Favorable for Vicals Phase 2 Trial of DNA Vaccine Against CMV
8. Roche Announces Positive Results in Solid Tumors Using Human Monoclonal Antibody Against IGF-1R (R1507)
9. Jennerex Presents Clinical Data From JX-594 Demonstrating Tumor Efficacy Against Advanced Liver Cancers
10. Semafores PI3 Kinase Inhibitor SF1126 is Active Against Tumor and Tumor Cells and Synergizes with Standard Chemotherapy Agents
11. BD and PEPFAR Collaborate to Strengthen Laboratory Systems in Fight Against HIV/AIDS and TB
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/19/2013)... 19, 2013  Omnicell, Inc. (NASDAQ: ... supply management solutions and analytics software for healthcare ... number one overall pharmacy equipment vendor in the ... a leading independent healthcare research firm, compared the ... its annual rankings. Omnicell also received the prestigious ...
(Date:6/19/2013)... , 19. Juni 2013 ... mit der Entwicklung von SCS microRESIST™, ... in der Beschichtung mit Parylene gelungen ... von biokompatiblem Parylene mit antimikrobiellen Eigenschaften ... schädlicher Mikroorganismen auf beschichteten medizinischen Geräten. ...
(Date:6/18/2013)... -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... VPII Escrow Corp., a newly formed wholly owned Canadian ... approximately $3.2 billion aggregate principal amount of senior unsecured ... 2021 and in 2023, with final tranching determined at ... net proceeds from the offering, together with proceeds from ...
Breaking Medicine Technology:Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 2Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 3Omnicell Named Top Vendor in 2013 KLAS Pharmacy Automation Equipment Rankings 4Specialty Coating Systems gibt die Einführung einer neuen antimikrobiellen Parylene-Technologie bekannt 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 2Valeant Pharmaceuticals Announces Launch Of Private Offering Of Senior Notes 3
... Pharmaceuticals, Inc. (OTC Bulletin Board: LTUS ... developer, manufacturer and seller of medicine and drugs ... announced that it plans to sell or transfer ... in the Chahaer Industrial Park, Inner Mongolia. Lotus, ...
... Inc. (OTC Bulletin Board: BHRT ) announced ... it finalized the formation of a working group. The ... clinical trial, combining a left ventricle assist device (LVAD) ... Bioheart,s MyoCath needle tipped catheter delivery system.   Initial ...
Cached Medicine Technology:Lotus Pharmaceuticals Announces Update on Land in Inner Mongolia 2Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial 2Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial 3Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial 4Bioheart Announces Plans to Advance LVAD + Muscle Stem Cells Clinical Trial 5
(Date:6/19/2013)... Casual, no-strings sexual encounters are increasingly common on ... than others to "hook up"? A new study ... Behavioral and Preventive Medicine, published online by the ... are certain factors and behaviors associated with sexual ... "Given the potential for negative emotional and physical ...
(Date:6/19/2013)... block the body,s system for repairing damage to the ... unlikely as it may seem, those compounds are sparking ... driven by a mutation in BRCA, a gene that ... the mutation. The compounds, termed PARP inhibitors, are the ... of Chemical & Engineering News . C&EN is ...
(Date:6/19/2013)... at Moffitt Cancer Center and colleagues at Louisiana State ... cancers that require immediate therapy. It relies on understanding ... goal is to better predict a prostate cancer,s aggressiveness ... was published in the online journal PLOS ONE ... cancer accounts for 20 percent of all cancers and ...
(Date:6/19/2013)... 19, 2013 Alternatives, a revolutionary new ... to quit using drugs while allowing them to continue ... founders of Alternatives, believe that abstinence-only approaches force people ... treatment and that this approach hurts instead of helping. ... the United States need treatment for addiction but only ...
(Date:6/19/2013)... Many trying-to-conceive couples seek medical ... according to a recent study published ... results of this research confirm what Fairhaven Health ... – that trying-to-conceive women would benefit from tracking ... weight. Fairhaven Health is a leading provider of ...
Breaking Medicine News(10 mins):Health News:Why are some college students more likely to 'hook up'? 2Health News:Moffitt Cancer Center researchers identify genetic variants predicting aggressive prostate cancers 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 2Health News:Top L.A. Addiction Experts Assert That an Abstinence-Only Approach to Addiction Keeps 85% of Addicts From Seeking Treatment 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 2Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 3Health News:Fairhaven Health's Dr. Amos Grunebaum Says Fertility Awareness Leads to Babies 4
... choosing a partner, women believe the lower the man,s voice, ... a woman with a higher voice is more likely to ... the latest edition of the online journal Evolutionary Psychology ... pitch and perceived infidelity and offers insight into the evolution ...
... Osteoarthritis - the most influential European bone meeting ... ,Palacio de Congresos, from March 23-26, 2011:,Register before ... of lower registration fees. Listen to ... Learn about key topics in 12 Meet-the-Professor Sessions, Take ...
... The combined effects of chemotherapy and endocrine therapy ... cancer survivors. In a study scheduled for publication in ... Medicine and Rehabilitation , researchers from the Oregon Health ... breast cancer survivors whether they had fallen in the ...
... HealthDay Reporter , THURSDAY, March 3 (HealthDay News) -- More ... than men are engaging in same-sex encounters, according to a ... In statistics compiled from interviews with 13,500 men and women ... Growth also indicates that more than half of young people ...
... (HealthDay News) -- Bunions, a common but painful deformity of the ... a new study has found. And the more severe the ... other parts of the body, leading to declines in both general ... is a bump that develops on the side of the big ...
... March 3, 2011 Unexpected results from a Scripps ... ideas about Alzheimer,s diseasepointing to the liver instead of the ... as brain plaques associated with this devastating condition. The findings ... treatment. The study was published online today in ...
Cached Medicine News:Health News:Can you predict your mate will cheat by their voice? 2Health News:Breast cancer survivors at higher risk for falls 2Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 2Health News:More Young People Delay Sex, Try Oral Sex First, CDC Says 3Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 2Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 3Health News:Scripps Research study points to liver, not brain, as origin of Alzheimer's plaques 4
PremierEdge Stab Knives - 30....
... for the total eye. Whether used ... mode or set independently to accommodate ... settings are adjustable to accommodate maximizing ... for use with tonometer-mounted, hand-held and ...
PremierEdge™ MVR Knives. Angled....
VISCO SHIELD Viscoelastic. Complete with 23g x 7/8" Thin Wall Cannula....
Medicine Products: